Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials-Reference-Cited by-同舟云学术

Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials

Published:2023-07 Issue:7 Volume:29 Page:509-516
ISSN:1530-891X
Container-title:Endocrine Practice
language:en
Short-container-title:Endocrine Practice

Author:

Singh Awadhesh Kumar^ORCID,Singh Akriti,Singh Ritu

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Reference40 articles.

1. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus;DeFronzo;Diabetes,2009

2. VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial;Matthews;Lancet,2019

3. Glycemia reduction in type 2 diabetes—glycemic outcomes;Nathan;N Engl J Med,2022

4. Diabetes monotherapies versus metformin-based combination therapy for the treatment of type 2 diabetes;Singh;Int J Gen Med,2021

5. Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences;Singh;Expert Rev Clin Pharmacol,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expert Consensus on Dipeptidyl Peptidase-4 Inhibitor-Based Therapies in the Modern Era of Type 2 Diabetes Mellitus Management in India;Cureus;2024-06-05

2. A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of MEtformin hydrochloride 1000 mg ER, SItagliptin phosphate 100 mg, and DApagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: The MESIDA trial;International Journal of Diabetes in Developing Countries;2024-02-17

3. Effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on serum uric acid levels in patients with chronic kidney disease: a systematic review and network meta-analysis;BMJ Open Diabetes Research & Care;2024-01